Observational studyHepatology (Baltimore, Md.)2020
Characterizing Hepatitis C Virus-Specific CD4
Observational study in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Therapeutic Vaccines for Chronic Viral Infections: From Immune Modulation to Clinical Translation.Vaccines · 2026Review
- Safety and Efficacy of Adoptive Transfer of Stem Cell Memory Enriched Virus Specific T Cells against CMV and EBV.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Activation-Induced Marker Assay to Identify and Isolate HCV-Specific T Cells for Single-Cell RNA-Seq Analysis.Viruses · 2024Article
- Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication.Clinical and molecular hepatology · 2024Review
- Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in the Host's Immunity.International journal of molecular sciences · 2023Review
- The use of adenoviral vectors in gene therapy and vaccine approaches.Genetics and molecular biology · 2022Article
- T cell responses during HBV and HCV infections: similar but not quite the same?Current opinion in virology · 2021Review
- Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial.Viruses · 2021Review
- Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection.Journal of clinical medicine · 2021Review
- Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.PloS one · 2021Article
- Lymphocyte Landscape after ChronicInternational journal of molecular sciences · 2020Review
- Adaptive Immune Response against Hepatitis C Virus.International journal of molecular sciences · 2020Review
- Reversal of T Cell Exhaustion in Chronic HCV Infection.Viruses · 2020Review
- Splenic CD4International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
aimsInduction of functional helper CD4 APPROACH AND
resultsWe analyzed HCV-specific CD4
conclusionsHelper CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.